Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1999-02-19
2001-11-06
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S204100, C424S199100, C424S816000, C424S252100, C435S236000, C435S235100, C435S320100, C530S350000
Reexamination Certificate
active
06312696
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to an antigen protein derived from infectious laryngotracheitis virus, its gene, a recombinant gene comprising that gene, and a vaccine for infectious laryngotracheitis having as its active ingredient said recombinant gene or the antigen protein.
RELATED ART
Infectious laryngotracheitis occurs due to infection by infectious laryngotracheitis virus (abbreviated as ILTV). ILTV infects chickens, pheasants, peacocks, turkeys and other fowls. Characteristics of its occurrence in chickens include respiratory organ symptoms, fever, reduced appetite and so forth. Intense cough and expectoration of sputum are observed. In addition; in egg-laying chickens, the rate at which eggs are laid decreases about 4 days after onset, and about 1 month is required for egg-laying to return to a normal level. Moreover, an increases in mortality rates due to mixed infection with other pathogens have also been reported, thus causing a tremendous economic loss in the poultry industry.
Dried live vaccines and frozen live vaccines from attenuated vaccine strains have conventionally been used for prevention of infectious laryngotracheitis. However, their immune effects vary considerablly depending on the breeding environment, breeding density, inoculation method and so forth. Moreover, inoculation of vaccine causes some symptoms in the respiratory system, and there is the risk of illness if errors are made in an administration manner or inoculated amount. In addition, there are also reports of onset of illness due to recovery of pathogenicity from the vaccine strain in certain geographical regions, thus creating the need for the development of a safe and effective vaccine.
ILTV is a type of Herpes virus. Its virus genome is composed of double-stranded DNA of approximately 160,000 base pairs. At present, very few genes are identified, and the only ones that are known are thymidine kinase gene (Griffin, et al., J. Gen. Virol., Vol. 71, p. 841, 1990), gp60 gene (Kongsuwan, et al., Virus Genes, Vol. 7, p. 297-303, 1993), capsid p40 gene (Griffin, Nucl. Acids Res., Vol. 18, p. 3664, 1990), glycoprotein B (gB) gene (Poulsen, et al., Virus Genes, Vol. 5, p. 335-347, 1991), glycoprotein C (gC) gene (Kingsley, et al., Virology, Vol. 203, p. 336-343, 1994), and RR2 gene (Griffin, J. Gen. Virol., Vol. 70, p. 3085-3089, 1989). In addition, several homologous genes are known to exist between each strain of Herpes virus. For example, there is an each homologous gene of gB in Herpes simplex virus (HSV-1), Marek's disease virus (MDV), Bovine Herpes virus (BHV), equine Herpes virus (EHV), cytomegalovirus (CMV) and so forth. However, although homologous genes are also reported in EHV with respect to UL32 gene of HSV-1 (Whittaker, et al., J. Gen. Virol., Vol. 73, p. 2933, 1992), there are as of yet no known homologous genes for ILTV. Moreover, the use of these genes for vaccines is also not known.
DISCLOSURE OF THE INVENTION
As a result of earnest studies to obtain a gene that encodes a novel antigen protein of ILTV considering the above-mentioned teaching, the inventors of the present invention found an ILTV homologous gene to UL32 gene of HSV-1, thereby leading to completion of the present invention.
According to the present invention, a polypeptide (referred to as UL32h polypeptide) is provided that has an amino acid sequence that is at least 80% homologous with the amino acid sequence described in SEQ ID No. 2.
In addition, the present invention provides a DNA molecule that encodes a protein having an amino acid sequence that is modified by deletion, addition and/or substitution by other amino acids of one or a plurality of amino acids in the amino acid sequence described in SEQ ID No. 2, and maintains the immunogenicity of infectious laryngotracheitis virus.
Moreover, the present invention provides a DNA molecule that encodes a protein that hybridizes with a nucleic acid having the nucleotide sequence described in SEQ ID No. 1 under conditions of 42° C., 2% skim milk, 6-fold concentrated SSC (6×SSC; pH 7.0) and 0.1% SDS, and still has the immunogenicity of infectious laryngotracheitis virus.
In addition, the present invention provides a recombinant DNA molecule comprising the above-mentioned DNA and at least one additional DNA sequence.
In addition, the present invention provides a recombinant vector that comprises the DNA sequence of any of the above-mentioned DNA molecules.
Moreover, the present invention provides a transformant host having any of the above-mentioned DNA molecules.
Moreover, the present invention provides a recombinant virus having any of the above-mentioned DNA molecules.
Moreover, the present invention provides a polypeptide having an amino acid sequence that is at least 80% homologous with the amino acid sequence described in SEQ ID No. 2.
Moreover, the present invention provides a protein having an amino acid sequence that is modified by deletion, addition and/or substitution by other amino acids of one or a plurality of amino acids in the amino acid sequence described in SEQ ID No. 2, and still maintains the immunogenicity of infectious laryngotracheitis virus.
Moreover, the present invention provides a protein encoded by DNA that hybridizes with a nucleic acid having the nucleotide sequence described in SEQ ID No. 1 under conditions of 42° C., 2% skim milk, 6-fold concentrated SSC (6×SSC; pH 7.0) and 0.1% SDS, and has the immunogenicity of infectious laryngotracheitis virus.
Moreover, the present invention provides a live vaccine for infectious laryngotracheitis virus having for its active ingredient the above-mentioned recombinant virus.
Moreover, the present invention provides a vaccine for infectious laryngotracheitis virus having for its active ingredient any of the above-mentioned polypeptides or its pharmacologically acceptable carrier.
REFERENCES:
Jennifer J. York et al; Archives of Virology; vol. 115, pp. 147-162, 1990.
Kritaya Kongsuwan et al; Virus Research; vol. 29, pp. 125-140, 1993.
Gary R. Whittaker et al; Journal of General Virology; vol. 73, pp. 2933-2940, 1992.
Okuda Takashi
Tsuzaki Yoshinari
Armstrong Westerman Hattori McLeland & Naughton LLP
Foley Shanon
Mosher Mary E.
Nippon Zeon Co., Ltd
LandOfFree
Antigenic protein originating in infectious... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigenic protein originating in infectious..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigenic protein originating in infectious... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2616651